NEW YORK (GenomeWeb News) – GeneWiz and Beijing ACCB Biotech today said they are collaborating on next-generation sequencing-based tests for the clinical market.

The firms are partnering to develop, validate, and commercialize genetic tests "that deliver clinically relevant, medically actionable results," they said. GeneWiz will develop and validate genetic testing methods that ACCB will then qualify and register. Using those methods, it will then produce diagnostic kits.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.